

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 10, 2004

Frank C. Eisenschenk, Ph.D., Patent Attorney



INFORMATION DISCLOSURE
STATEMENT
Examining Group 1614
Patent Application
Docket No. UF-389
Serial No. 10/700,156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1614
Applicants : Nathan Andrew Shapira, Giselle D. Mann, April M. Annis,
Toby Doris Goldsmith
Serial No. : 10/700,156
Filed : November 3, 2003
For : Methods to Prevent or Ameliorate Medication-, Procedure- or Stress-Induced
Cognitive and Speech Dysfunction and Methods to Optimize Cognitive and
Speech Functioning

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	1	of	2	Application Number	10/700,156
				Filing Date	November 3, 2003
				First Named Inventor	Nathan Andrew Shapira
				Group Art Unit	1614
				Examiner Name	
				Attorney Docket Number	UF-389

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	DUGGLEBY, W. and LANDER, J. "Cognitive status and postoperative pain: older adults" <i>J. Pain Symptom Management</i> , 1994, 9(1):19-27.		
	R2	ELLIS, K. et al. "Post-craniectomy intracranial hypotension: potential impact on rehabilitation" <i>Brain Inj.</i> , 1998, 12(10):895-899.		
	R3	HADDOCK, C.K. et al. "Neurocognitive sequelae following coronary bypass graft. A research agenda for behavioral scientists" <i>Behav. Modif.</i> , 2003, 27(1):68-82.		
	R4	HEYER, E.J. et al. "A controlled prospective study of neuropsychological dysfunction following carotid endarterectomy" <i>Arch. Neurol.</i> , 2000, 59(2):217-222.		
	R5	HIRSCH, C.H. "When you patient needs surgery: how planning can avoid complications" <i>Geriatrics</i> , 1995, 50(2):39-44.		
	R6	KOURIDOU-PAPADELI, C. et al. "Maximum cognitive performance and physiological time trend measurements after caffeine intake" <i>Brain Cogn. Brain Res.</i> , 2002, 13(3):407-415.		
	R7	LANE, J. "Effect of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance" <i>Phar. Bio. and Beh.</i> , 1997, 58(1):203-208.		
	R8	LIEBERMAN, H.R. "The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood, and energy" <i>Nutr. Rev.</i> , 2001, 59(4):91-201.		
	R9	MICHELSON, D. et al. "Atomoxetine in adults with ADHD: two randomized placebo controlled studies" <i>Biol. Psychiatry</i> , 2003:112-120.		
	R10	NEYLAN, T.C. et al. "Cortisol levels predict cognitive impairment induced by electroconvulsive therapy" <i>Biol. Psychiatry</i> 2001, 50(5):331-336.		
	R11	PETTY, F. et al. "Serotonin dysfunction disorders: a behavioral neurochemistry perspective" <i>J. Clin. Psychiatry</i> , 1996, 57 Supp 8:11-16.		
	R12	PHILLIPS, G.M. and SOKOLOFF, K.A. "An end to anxiety treating speech problems with rhetoritherapy" <i>J. Commun. Disord.</i> , 1979, 12(5):385-397.		
	R13	PLISZKA, S.R. "Non-stimulant treatment of attention-deficit/hyperactivity disorder" <i>CNS Spectr.</i> , 2003, 8(4):253-258.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/700,156
Filing Date	November 3, 2003
First Named Inventor	Nathan Andrew Shapira
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	UF-389

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
R14	SCHANEBERG, B.T. et al. "The role of chemical fingerprinting: application to ephedra: phytochemistry" _____, 2003, 62(6):911-918.	T ²
R15	SMIT, H.J. and ROGERS, P.J. "Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers" <i>Psychopharmacology</i> , 2000, 152(2):167-173.	
R16	VAN DER HOOFT, C.S. and STRICKER, B.H. "Ephedrine and ephedra in weight loss products and other preparations" <i>Ned Tijdschr Geneeskd.</i> , 2002, 146(28):13335-13336.	
R17		
R18		
R19		
R20		
R21		
R22		
R23		
R24		
R25		
R26		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.